1Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release, inhibiting factor (SRIF) receptor binding and a unique antiseeretory profile[J]. Eur J Endocrino1,2002,146(5):707-716.
3Barrie R, Woltefing EA, Hajarizatteh H, et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compomMs is structttrally dependent[J]. J Surg Res, 1993,55(4):446-450.
4Charland S, Boueher MJ, Houde M, et al. Somatostatin inhibits Akt phosphorylation and cell cycle entry but not p42/p44 mitogen-actlvated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells[J]. Endocrinology ,2001,142(1):121-128.
5Marion-Audibert AM, Nejjari M, Pourreyron C, et al. Effects des peptides endocrines sur la proliferation, la migration et la differenciation des cellules endotheliales humaines[J]. Gastroenterol Clin Biol, 2000,24(6-7): 644-648.
6Corsaro A, Thelltmg S, Villa V, et al. Somatostatinergic control of Kaposi's sarcoma growth through the inhibition of angiogenesis[J]. Mineroa Endocrinol, 2001,26(4): 273-276.
7Solomou K, Ritter MA, Palmer DB. Somatostatin is expressed in the murine thymus and enhances thymocyte development[J]. Eur J Immunol, 2002,32(6):1 550-1 559.
8Ueta E, Yoneda K, Kimura T,et al. Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and ganunarays regulating expression of the Bcl-2 family proteins, COX-2 and p21[J]. Int J Cancer,2001,94(4):545-550.
9Cardoso A, el-Ghamrawy C, Gantron JP, et al. Somatostatin increases mitogen-induced IL-2 secretion and proliferation of human Jurkat T cells via sst3 receptor isotype[J]. J Cell Biochem, 1998,68(1):62-73.
10Georgii-Hemnring P, Stromberg T, Janson ET, et al. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines[J]. Blood, 1999,93(5):1 724-1 731.
